Price Chart

Executive Summary

Regeneron announced FDA and EMA acceptance of regulatory applications for cemdisiran, an investigational siRNA therapy for generalized myasthenia gravis (gMG). The FDA granted Priority Review with a target action date in November 2026, and the EMA decision is expected in H2 2027. This is a significant pipeline catalyst for Regeneron, as cemdisiran could become the first siRNA approved for gMG with a convenient subcutaneous dosing schedule four times a year.

Key Facts

• FDA accepted NDA for cemdisiran under Priority Review; target action date November 2026.
• EMA accepted regulatory application; decision anticipated H2 2027.
• Cemdisiran is an investigational siRNA targeting C5 for anti-AChR antibody-positive gMG.
• Phase 3 NIMBLE trial data published in The Lancet and presented at AAN 2026.
• Subcutaneous dosing every 12 weeks (four times a year) — potential convenience advantage.
• Regeneron is solely responsible for development, manufacturing, and commercialization via Alnylam licensing agreement.
• Priority Review Voucher used for the NDA submission.
• gMG affects ~85,000 people in the U.S.; estimated 150-200 per million globally.

Financial Impact

Cemdisiran targets a large gMG market (~85,000 U.S. patients) with potential to become first siRNA approved for the indication. No revenue or deal value disclosed.

Risk Factors

• Regulatory risk: FDA may issue a Complete Response Letter (CRL) despite Priority Review.
• Competition: existing gMG therapies (e.g., Soliris, Vyvgart) and other pipeline candidates could limit market share.
• Commercialization risk: pricing, reimbursement, and physician adoption uncertainties.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status

Related Tickers